PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33023784-0	2020	Imiquimod-induced dermatitis impairs thymic tolerance of autoreactive CD4+ T cells to desmoglein 3.	Imiquimod	0-9	CD4 antigen	Mus musculus	70-73	
33007409-8	2020	Our data display that ITK signaling is involved in IMQ-induced psoriatic inflammation as paralleled by enhancement of p-ITK, NFATc1, p-NFkB and p-STAT3 in CD4+ T cells.	Imiquimod	51-54	CD4 antigen	Mus musculus	155-158	
33023784-12	2020	Although Dsg3-sepcific transgenic thymocytes was usually deleted in the thymus under physiological condition by central tolerance, Dsg3-sepcific transgenic CD4+CD8- thymocytes significantly increased in number under imiquimod-induced dermatitis.	Imiquimod	216-225	CD4 antigen	Mus musculus	156-159	
31678366-5	2020	Compared to controls, IMQ-treated neutropenic mice had significantly lower levels of macrophages in tissue samples (P < .05) and displayed significantly lower numbers of CD4+ T-cells (P < .05).	Imiquimod	22-25	CD4 antigen	Mus musculus	170-173	
31773789-5	2020	We found that topical treatment with NG-anti-miR-210 significantly decreased the expression of miR-210 in both the skin lesions and splenic CD4+ T cells from IMQ-induced psoriasis-like mouse models and ameliorated the dermatitis in terms of the erythema, scales, acanthosis and dermal inflammatory cell infiltration in IMQ-induced mice.	Imiquimod	158-161	CD4 antigen	Mus musculus	140-143	
31773789-5	2020	We found that topical treatment with NG-anti-miR-210 significantly decreased the expression of miR-210 in both the skin lesions and splenic CD4+ T cells from IMQ-induced psoriasis-like mouse models and ameliorated the dermatitis in terms of the erythema, scales, acanthosis and dermal inflammatory cell infiltration in IMQ-induced mice.	Imiquimod	319-322	CD4 antigen	Mus musculus	140-143	
31393597-3	2019	To overcome this limitation, we developed a novel imiquimod-containing vaccination platform (IMI-Sol) rendering superior primary CD8+ and CD4+ T-cell responses.	Imiquimod	50-59	CD4 antigen	Mus musculus	138-141	
31407330-12	2019	Kaempferol also lowered the percentage of IL-17A+ CD4+ T cells in the spleen and lymph nodes of IMQ-induced psoriatic mice.	Imiquimod	96-99	CD4 antigen	Mus musculus	50-53	
30834454-6	2019	Inhibition of sphingosine kinase 2, but not sphingosine kinase 1, diminished levels of suppressor of cytokine signalling 1 and blocked T helper type 17 differentiation of naive CD4+ T cells; imiquimod-induced psoriasis-like skin symptoms were also ameliorated.	Imiquimod	191-200	CD4 antigen	Mus musculus	177-180	
35562873-8	2022	Imiquimod-induced increases in the CD4+IL-17A+ T cell population in lymph nodes and spleens were suppressed by Compound A treatment in FFA4 WT mice; however, this was not seen in FFA4 KO mice.	Imiquimod	0-9	CD4 antigen	Mus musculus	35-38	
34364883-10	2022	Further, IMQ increased CD8+ and CD4+ T cell infiltration in TG>WT>KO mice.	Imiquimod	9-12	CD4 antigen	Mus musculus	32-35	
34537997-6	2021	Besides, we found that imiquimod upregulated the expression of OX40 on CD4+ T cells and thus enhanced the effectiveness of OX40 agonist.	Imiquimod	23-32	CD4 antigen	Mus musculus	71-74	
21389872-6	2011	Aldara treatment was associated with a reduction in the number CD4(+)Foxp3(+) regulatory T cells in the blood and brain tumor site.	Imiquimod	0-6	CD4 antigen	Mus musculus	63-66	
21389872-7	2011	Mice treated with Aldara exhibited a generalized lymphopenia in the blood amidst an increase in brain tumor infiltrating CD4(+) and CD8(+) T cells and dendritic cells.	Imiquimod	18-24	CD4 antigen	Mus musculus	121-124	
34931339-0	2022	Decreased microRNA-126 expression in psoriatic CD4+ T cells promotes T-helper 17 cell differentiation and the formation of dermatitis in imiquimod-induced psoriasis-like mice.	Imiquimod	137-146	CD4 antigen	Mus musculus	47-50	
34931339-4	2022	Conditional Mir126 knockout in mouse CD4+ T cells can obviously aggravate the psoriasis-like dermatitis and promote T-helper (Th)1 and Th17 cells" infiltration in spleen of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	173-182	CD4 antigen	Mus musculus	37-40	
34931339-4	2022	Conditional Mir126 knockout in mouse CD4+ T cells can obviously aggravate the psoriasis-like dermatitis and promote T-helper (Th)1 and Th17 cells" infiltration in spleen of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	184-187	CD4 antigen	Mus musculus	37-40	
35173615-9	2022	Compared with WT mice, CB2R deficiency exacerbated IMQ-induced PsD and scratching bouts and upregulated the expression of proinflammatory cytokines by increasing the infiltration of CD4+ T cells and the Th17/Treg ratio.	Imiquimod	51-54	CD4 antigen	Mus musculus	182-185